Eptifibatide
Based on 9 publication(s) in Google Scholar
Eptifibatide is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.79%
- CAS No.: 188627-80-7
- Formule: C35H49N11O9S2
- Masse moléculaire:831.96
-
Stockage:
Sealed storage, away from moisture and light.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Eptifibatide
More- Nat Commun. 2024 Apr 11;15(1):3129. [Abstract]
- Pharmacol Res. 2021 May:167:105540. [Abstract]
- Life Sci. 2026 Jan 15:385:124138. [Abstract]
- Int J Mol Sci. 2021 Mar 24;22(7):3323. [Abstract]
- Am J Respir Cell Mol Biol. 2025 Feb 28. [Abstract]
- Platelets. 2024 Dec;35(1):2308635. [Abstract]
- J Thromb Thrombolysis. 2025 Sep 9. [Abstract]
- University of Bonn. 2023 May 31.
- Ghent University. 2018 May.
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Histological Imaging/Staining
-
In Vivo Efficacy Study
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Platelet | IC50 |
0.012 μM
Compound: Eptifibatide
|
Antiplatelet activity in platelet (unknown origin) assessed as inhibition of platelet aggregation
Antiplatelet activity in platelet (unknown origin) assessed as inhibition of platelet aggregation
|
[PMID: 24461295] |
Eptifibatide is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 188627-80-7
-
Appearance Solid
-
Masse moléculaire 831.96
-
Formule C35H49N11O9S2
-
Color White to off-white
-
Sequence
MPA-HAR-Gly-Asp-Trp-Pro-Cys-NH2
-
Sequence Shortening
MPA-HAR-GDWPC-NH2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture and light
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Protein disulfide isomerase cleaves allosteric disulfides in histidine-rich glycoprotein to regulate thrombosis. [Abstract]2024 Apr 11;15(1):3129. PMID: 38605050
Eptifibatide purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Apr 11;15(1):3129. [Abstract]
The median fluorescence intensity of HRG and platelets were calculated and plotted over time from mice treated or untreated with Eptifibatide (10 μg/g body weight, repeated every 15-20 min).
Eptifibatide purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Apr 11;15(1):3129. [Abstract]
The scatter plot of pixel intensities of green (HRG) and red (CD31) fluorescence in ROI1 and ROI2 as indicated were presented. The Pearson's correlation coefficients (r) for pixels with intensity above the threshold (indicated by the dashed lines) in the thrombus (ROI2) and in the area without the thrombus (ROI1-ROI2) were inserted. Veh vehicle, Epti eptifibatide.
Eptifibatide purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Apr 11;15(1):3129. [Abstract]
When mice were treated with eptifibatide, an integrin αIIbβ3 antagonist that eliminated platelet deposition and thus platelet-derived Zn2+, HRG accumulation at the site of vessel injury was significantly reduced by 58.3%.
-
Pharmacol Res
Anti-thrombotic effects mediated by dihydromyricetin involve both platelet inhibition and endothelial protection. [Abstract]2021 May:167:105540. PMID: 33711433 -
Life Sci
Mechanistic insights into PPARγ's role in suppressing collagen-driven platelet activation. [Abstract]2026 Jan 15:385:124138. PMID: 41354414 -
Int J Mol Sci
A Combined Activity of Thrombin and P-Selectin Is Essential for Platelet Activation by Pancreatic Cancer Cells. [Abstract]2021 Mar 24;22(7):3323. PMID: 33805059 -
Am J Respir Cell Mol Biol
GP IIb/IIIa-ICAM-1 Mediated Platelet-Endothelial Adhesion Exacerbates Pulmonary Hypertension. [Abstract]2025 Feb 28. PMID: 40019848 -
Platelets
2024 Dec;35(1):2308635. PMID: 38345065 -
J Thromb Thrombolysis
The inhibitory effect of antiplatelet drugs on spontaneous platelet aggregation on glass surfaces: an analysis based on microscopic three-dimensional topography. [Abstract]2025 Sep 9. PMID: 40924280 -
-
Eptifibatide purchased from MedChemExpress. Usage Cited in: Ghent University. 2018 May.
Concentration eptifibatide in function of buffer volume eluted from the column.
Eptifibatide purchased from MedChemExpress. Usage Cited in: Ghent University. 2018 May.
Calibration curve eptifibatide (0.25 mg/mL-0,00012207 mg/mL).
Solvant et solubilité
DMSO : 200 mg/mL (240.40 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 50 mg/mL (60.10 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (2.50 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (2.50 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (120.20 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Pureté et documentation
-
Fiche technique (274 KB)
-
SDS (420 KB)
- English - EN (420 KB)
- Français - FR (420 KB)
- Deutsch - DE (420 KB)
- Norwegian - NO (420 KB)
- Español - ES (420 KB)
- Swedish - SV (420 KB)
- Italian - IT (420 KB)
- Korean - KR (420 KB)
- Portuguese - PT (420 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 1.2020 mL | 6.0099 mL | 12.0198 mL | 30.0495 mL |
| 5 mM | 0.2404 mL | 1.2020 mL | 2.4040 mL | 6.0099 mL | |
| 10 mM | 0.1202 mL | 0.6010 mL | 1.2020 mL | 3.0050 mL | |
| 15 mM | 0.0801 mL | 0.4007 mL | 0.8013 mL | 2.0033 mL | |
| 20 mM | 0.0601 mL | 0.3005 mL | 0.6010 mL | 1.5025 mL | |
| 25 mM | 0.0481 mL | 0.2404 mL | 0.4808 mL | 1.2020 mL | |
| 30 mM | 0.0401 mL | 0.2003 mL | 0.4007 mL | 1.0017 mL | |
| 40 mM | 0.0300 mL | 0.1502 mL | 0.3005 mL | 0.7512 mL | |
| 50 mM | 0.0240 mL | 0.1202 mL | 0.2404 mL | 0.6010 mL | |
| 60 mM | 0.0200 mL | 0.1002 mL | 0.2003 mL | 0.5008 mL | |
| DMSO | 80 mM | 0.0150 mL | 0.0751 mL | 0.1502 mL | 0.3756 mL |
| 100 mM | 0.0120 mL | 0.0601 mL | 0.1202 mL | 0.3005 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Eptifibatide Related Classifications
HY-B0686 Related Classifications
Powered by Bioz